Inhibition TOP2A results in alterations of signaling and the following pathways: overexpression of TOP2A actives β-catenin pathway in pancreatic cancer 12; downregulation of TOP2A inhibits the activity of EPK and AKT in colon cancer 15. This evidence concerns the gene TOP2A and familial pancreatic carcinoma.